Sven H Loosen1, Karel Kostev2, Tom Luedde1, Christoph Roderburg3, Mark Luedde4. 1. Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. 2. Epidemiology, IQVIA, Frankfurt, Germany. 3. Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. Christoph.Roderburg@med.uni-duesseldorf.de. 4. KGP Bremerhaven, Bremerhaven, Germany.
Abstract
PURPOSE: There is a growing body of evidence suggesting a decisive involvement of the human lipid metabolism in cancer development. However, clinical data on the association between blood triglyceride or cholesterol levels including the cholesterol transporters high-density and low-density lipoproteins (LDL, HDL) and cancer incidence have remained inconclusive. Here, we investigated the association between blood triglyceride as well as total, LDL and HDL cholesterol levels and cancer among outpatients from Germany. METHODS: 61,936 patients with available blood lipid values were identified from the IQVIA Disease Analyzer database and followed up between 2005 and 2019. Multivariable logistic regression models were used to study the association between lipid values and cancer. RESULTS: The probability of cancer was significantly lower among patients with elevated total cholesterol concentrations and higher in patients with decreased HDL serum levels. In contrast, serum concentrations of LDL and triglycerides had no impact on cancer risk. In cancer site-stratified analyses, we observed a trend towards higher rates of cancers from digestive organs, breast, skin cancer, urinary tract and cancers from lymphoid and hematopoietic tissue in patients with HDL values < 35 mg/dl, while a negative association between total cholesterol > 250 mg/dl and respiratory organ as well as urinary tract cancers was observed. CONCLUSION: Our data strongly support the hypothesis that serum-specific lipid profiles are positively associated with cancer.
PURPOSE: There is a growing body of evidence suggesting a decisive involvement of the human lipid metabolism in cancer development. However, clinical data on the association between blood triglyceride or cholesterol levels including the cholesterol transporters high-density and low-density lipoproteins (LDL, HDL) and cancer incidence have remained inconclusive. Here, we investigated the association between blood triglyceride as well as total, LDL and HDL cholesterol levels and cancer among outpatients from Germany. METHODS: 61,936 patients with available blood lipid values were identified from the IQVIA Disease Analyzer database and followed up between 2005 and 2019. Multivariable logistic regression models were used to study the association between lipid values and cancer. RESULTS: The probability of cancer was significantly lower among patients with elevated total cholesterol concentrations and higher in patients with decreased HDL serum levels. In contrast, serum concentrations of LDL and triglycerides had no impact on cancer risk. In cancer site-stratified analyses, we observed a trend towards higher rates of cancers from digestive organs, breast, skin cancer, urinary tract and cancers from lymphoid and hematopoietic tissue in patients with HDL values < 35 mg/dl, while a negative association between total cholesterol > 250 mg/dl and respiratory organ as well as urinary tract cancers was observed. CONCLUSION: Our data strongly support the hypothesis that serum-specific lipid profiles are positively associated with cancer.
Authors: G Oliveras; A Blancafort; A Urruticoechea; O Campuzano; D Gómez-Cabello; R Brugada; M L López-Rodríguez; R Colomer; T Puig Journal: Ann N Y Acad Sci Date: 2010-10 Impact factor: 5.691
Authors: Laurent Yvan-Charvet; Tamara Pagler; Emmanuel L Gautier; Serine Avagyan; Read L Siry; Seongah Han; Carrie L Welch; Nan Wang; Gwendalyn J Randolph; Hans W Snoeck; Alan R Tall Journal: Science Date: 2010-05-20 Impact factor: 47.728
Authors: Paulette D Chandler; Yiqing Song; Jennifer Lin; Shumin Zhang; Howard D Sesso; Samia Mora; Edward L Giovannucci; Kathryn E Rexrode; M Vinayaga Moorthy; Chunying Li; Paul M Ridker; I-Min Lee; JoAnn E Manson; Julie E Buring; Lu Wang Journal: Am J Clin Nutr Date: 2016-04-20 Impact factor: 7.045
Authors: Paul Nderitu; Cecilia Bosco; Hans Garmo; Lars Holmberg; Håkan Malmström; Niklas Hammar; Göran Walldius; Ingmar Jungner; Paul Ross; Mieke Van Hemelrijck Journal: Int J Cancer Date: 2017-06-21 Impact factor: 7.396
Authors: Pedro M R Cruz; Huanbiao Mo; Walter J McConathy; Nirupama Sabnis; Andras G Lacko Journal: Front Pharmacol Date: 2013-09-25 Impact factor: 5.810
Authors: Christian Labenz; Yvonne Huber; Maurice Michel; Michael Nagel; Peter R Galle; Karel Kostev; Jörn M Schattenberg Journal: Hepatol Commun Date: 2020-06-22
Authors: Sven H Loosen; Christoph Roderburg; Markus S Jördens; Georg Fluegen; Tom Luedde; Karel Kostev Journal: Cancers (Basel) Date: 2022-02-13 Impact factor: 6.639
Authors: Sven H Loosen; David Schöler; Simon Labuhn; Alexander Mertens; Markus S Jördens; Mark Luedde; Karel Kostev; Tom Luedde; Christoph Roderburg Journal: Cancers (Basel) Date: 2022-08-06 Impact factor: 6.575